Cloprostenol

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 461123

CAS#: 40665-92-7

Description: Cloprostenol is a synthetic prostaglandin analogue.

Chemical Structure

img
Cloprostenol
CAS# 40665-92-7
Instruction

Theoretical Analysis

MedKoo Cat#: 461123
Name: Cloprostenol
CAS#: 40665-92-7
Chemical Formula: C22H29ClO6
Exact Mass: 424.17
Molecular Weight: 424.910
Elemental Analysis: C, 62.19; H, 6.88; Cl, 8.34; O, 22.59

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Cloprostenol; Estrofan; Oestrophan;

IUPAC/Chemical Name: (Z)-7-((1R,2R,3R,5S)-2-((R,E)-4-(3-chlorophenoxy)-3-hydroxybut-1-en-1-yl)-3,5-dihydroxycyclopentyl)hept-5-enoic acid

InChi Key: VJGGHXVGBSZVMZ-QIZQQNKQSA-N

InChi Code: InChI=1S/C22H29ClO6/c23-15-6-5-7-17(12-15)29-14-16(24)10-11-19-18(20(25)13-21(19)26)8-3-1-2-4-9-22(27)28/h1,3,5-7,10-12,16,18-21,24-26H,2,4,8-9,13-14H2,(H,27,28)/b3-1-,11-10+/t16-,18-,19-,20+,21-/m1/s1

SMILES Code: Clc1cccc(OC[C@H](O)/C=C/[C@H]2[C@H](O)C[C@H](O)[C@@H]2C/C=C\CCCC(O)=O)c1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 424.91 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Bourne GR, Moss SR, Phillips PJ, Shuker B. The disposition of the synthetic prostaglandin analogue cloprostenol ('Estrumate') in the rat and marmoset. Xenobiotica. 1979 Oct;9(10):623-31. PubMed PMID: 119354.

2: Re G, Badino P, Novelli A, Vallisneri A, Girardi C. Specific binding of dl-cloprostenol and d-cloprostenol to PGF2 alpha receptors in bovine corpus luteum and myometrial cell membranes. J Vet Pharmacol Ther. 1994 Dec;17(6):455-8. PubMed PMID: 7707491.

3: Choi YM, Diehl J, Levins PC. Promising alternative clinical uses of prostaglandin F2α analogs: beyond the eyelashes. J Am Acad Dermatol. 2015 Apr;72(4):712-6. doi: 10.1016/j.jaad.2014.10.012. Epub 2015 Jan 16. Review. PubMed PMID: 25601618.

4: Lin L, Zhao YJ, Chew PT, Sng CC, Wong HT, Yip LW, Wu TS, Bautista D, Teng M, Khoo AL, Lim BP. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension. Ann Pharmacother. 2014 Dec;48(12):1585-93. doi: 10.1177/1060028014548569. Epub 2014 Sep 2. PubMed PMID: 25184309.

5: Stevens RD, Seguin BE, Momont HW. Evaluation of the effects of route of administration of cloprostenol on synchronization of estrus in diestrous dairy cattle. J Am Vet Med Assoc. 1995 Jul 15;207(2):214-6. PubMed PMID: 7601719.

6: Cate H, Bhattacharya D, Clark A, Fordham R, Holland R, Broadway DC. Improving adherence to glaucoma medication: a randomised controlled trial of a patient-centred intervention (The Norwich Adherence Glaucoma Study). BMC Ophthalmol. 2014 Mar 24;14:32. doi: 10.1186/1471-2415-14-32. PubMed PMID: 24655814; PubMed Central PMCID: PMC3994324.

7: Prévost S, Thai K, Schützenmeister N, Coulthard G, Erb W, Aggarwal VK. Synthesis of prostaglandin analogues, latanoprost and bimatoprost, using organocatalysis via a key bicyclic enal intermediate. Org Lett. 2015 Feb 6;17(3):504-7. doi: 10.1021/ol503520f. Epub 2015 Jan 12. PubMed PMID: 25582321.

8: Franca JR, Foureaux G, Fuscaldi LL, Ribeiro TG, Rodrigues LB, Bravo R, Castilho RO, Yoshida MI, Cardoso VN, Fernandes SO, Cronemberger S, Ferreira AJ, Faraco AA. Bimatoprost-loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: in vitro and in vivo evaluation. PLoS One. 2014 Apr 30;9(4):e95461. doi: 10.1371/journal.pone.0095461. eCollection 2014. PubMed PMID: 24788066; PubMed Central PMCID: PMC4005758.

9: Bourne GR, Moss SR, Phillips PJ, Webster JT, White DF. Ion cluster techniques in drug metabolism: an example of the use of mixtures of the [12C]:[14C] isotopic forms of the synthetic prostaglandin cloprostenol ('Estrumate') to facilitate metabolite identification. Biomed Mass Spectrom. 1979 Aug;6(8):359-60. PubMed PMID: 497363.

10: Li J, Lin X, Yu M. Meta-analysis of randomized controlled trials comparing latanoprost with other glaucoma medications in chronic angle-closure glaucoma. Eur J Ophthalmol. 2015 Jan-Feb;25(1):18-26. doi: 10.5301/ejo.5000506. Epub 2014 Jul 8. PubMed PMID: 25044139.

11: Kawai-Tsuboi N, Kawai M, Minami Y, Yoshida A. A study of the association between patterns of eye drop prescription and medication usage in glaucoma subjects. J Glaucoma. 2015 Mar;24(3):202-6. doi: 10.1097/IJG.0b013e31829e1b8b. PubMed PMID: 23807351.

12: Kucukevcilioglu M, Bayer A, Uysal Y, Altinsoy HI. Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost. Clin Exp Ophthalmol. 2014 Mar;42(2):126-31. doi: 10.1111/ceo.12163. Epub 2013 Aug 4. PubMed PMID: 23844550.

13: Macky TA. Bimatoprost/timolol versus travoprost/timolol fixed combinations in an Egyptian population: a hospital-based prospective randomized study. J Glaucoma. 2014 Oct-Nov;23(8):561-6. doi: 10.1097/IJG.0b013e3182867be3. PubMed PMID: 23429621.

14: Rao RC, Ballard TN, Chen TC. Iris heterochromia and unilateral eyelash hypertrichosis. JAMA. 2015 May 19;313(19):1967-8. doi: 10.1001/jama.2015.1348. PubMed PMID: 25988467; PubMed Central PMCID: PMC4499467.

15: Zhang C. Influence of local application of glaucoma medications-travoprost eye drops on patients' tear film function. Pak J Pharm Sci. 2015 Mar;28(2 Suppl):781-4. PubMed PMID: 25796154.

16: Karslioğlu MZ, Hoşal MB, Tekeli O. Periocular changes in topical bimatoprost and latanoprost use. Turk J Med Sci. 2015;45(4):925-30. PubMed PMID: 26422869.

17: Chen W, Dong N, Huang C, Zhang Z, Hu J, Xie H, Pan J, Liu Z. Corneal alterations induced by topical application of commercial latanoprost, travoprost and bimatoprost in rabbit. PLoS One. 2014 Mar 14;9(3):e89205. doi: 10.1371/journal.pone.0089205. eCollection 2014. Erratum in: PLoS One. 2014;9(5):e98378. PubMed PMID: 24632558; PubMed Central PMCID: PMC3954555.

18: Lipatov DV, Chistyakov TA, Kuzmin AG, Tolkacheva AA. The fixed combination efficacy assessment in patients with secondary neovascular glaucoma and diabetes mellitus. Curr Diabetes Rev. 2015;11(4):281-4. PubMed PMID: 26004082.

19: Fukuda M, Sasaki H. The transcorneal penetration of commercial ophthalmic formulations containing timolol maleate in rabbit eyes. J Ocul Pharmacol Ther. 2015 Feb;31(1):57-60. doi: 10.1089/jop.2014.0015. PubMed PMID: 25303115.

20: Wang K, Xu L, Yuan Z, Yao K, Zhao J, Xu L, Fang A, Zhang M, Wu L, Ji J, Hou J, Liu Q, Sun X. Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China. BMC Ophthalmol. 2014 Feb 25;14:21. doi: 10.1186/1471-2415-14-21. PubMed PMID: 24568617; PubMed Central PMCID: PMC3943806.